Jul 01,2021

Insulet to Announce Second Quarter 2021 Financial Results on August 5, 2021

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2021 on August 5, 2021 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Jul 02,2021

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Senseonics Holdings, a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a).

View Analyst & Ambassador Comments
Go to original news
Jul 03,2021

An Integrated Mobile Platform for Automated Data Collection and Real-Time Patient Monitoring in Diabetes Clinical Trials

We present a new mobile platform to be used in clinical trials aimed at both collecting data and assessing new technologies and treatments for diabetes care. The main components of the platform are a mobile app, that automatically collects data from continuous glucose monitoring sensors and activity trackers, and also allows users to manually log daily events; a cloud database for safe data storage; a web interface, which allows clinicians to monitor patients’ status in real-time.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 05,2021

Appointment of an independent expert as part of the planned acquisition of Voluntis by Aptar

Voluntis, announces that the Board of Directors of the Company has appointed an independent expert in in the context of the planned acquisition of a controlling block and the filing, subject to and following this acquisition, of a simplified public tender offer in cash (the "Offer") for the shares of Voluntis which would be followed by a squeeze-out if regulatory conditions are met(1), by AptarGroup, Inc. a global leader in the packaging of pharmaceutical products and consumer goods.

View Analyst & Ambassador Comments
Go to original news
Jul 05,2021

The Accuracy of Continuous Glucose Monitoring in the Medical Intensive Care Unit

A Medtronic Enlite® sensor accuracy was assessed versus capillary blood glucose (CBG) and plasma glucose (PG) using the mean absolute relative difference (MARD), surveillance error grid (SEG) analysis and modified Bland-Altman plots.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 05,2021

Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018

The IBM® MarketScan® Commercial and Medicare databases were used to identify trends in insulin use over 10 years. The study included people with T1D or T2D who filled a prescription for insulin in any calendar year from 2009 to 2018. The analyses examined insulin regimen and delivery and the use of glucose monitoring systems. Generalized estimating equations were used to test whether trends were statistically significant.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 06,2021

Brighter carries out a private placement of SEK 5 million

The Board of Directors of Brighter has, under the authorization from the AGM of 2020, decided on a new share issue of a total of SEK 5 million. Payment will be made in cash. The amount of cash received will be used in full to repay previous loans from these lenders.

View Analyst & Ambassador Comments
Go to original news
Jul 12,2021

BD Announces Two Future Directors for Diabetes Care Spinoff Company

BD, a leading global medical technology company, today announced that David F. Melcher will be non-executive chair of the board of directors, and Claire Pomeroy, MD, MBA, will be a director of the company formed in connection with the previously announced separation of the Diabetes Care business into an independent, publicly traded company ("NewCo").

View Analyst & Ambassador Comments
Go to original news
Jul 12,2021

Tandem Diabetes Care to Announce Second Quarter 2021 Financial Results on August 4, 2021

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, plans to release its second quarter 2021 results after the financial markets close on Wednesday, August 4, 2021. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2021 financial and operating results.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 12,2021

Nemaura Medical to Present at the Access to Giving Virtual Investor Conference on July 13, 2021

Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES